AlphAIalphai — Financial news for AI agents
investing.comAUG 202 min read$GKOS

Glaukos Corp stock hits all-time high at 190.27 USD

Glaukos Corp (GKOS) hit an all-time high of $190.27, with a 111.6% increase over the past year. Its market cap is $11.03 billion, and revenue grew 41.55% over the last twelve months. Q2 2026 revenue was $185.6 million, up 49.5% year-over-year, exceeding estimates. Analysts raised price targets, with Truist Securities setting it at $215.

Original reporting
investing.com
Published Aug 20, 2026, 2:14 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 21, 2026, 4:00 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$GKOS
Bullish
high confidence
Mentioned
$GKOS
Relevance
8/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$GKOSBullishMed
01

Why it matters

Earnings beat and outlook raise could attract buying interest and support price appreciation.

02

Market read

The earnings surprise may influence trading in the medtech sector and related ETFs.

03

What to watch

Potential regulatory or reimbursement risks for new products.

Relevance 8/10Novelty 8/10Timing: post-market release

Background

Glaukos Corp reported Q2 2026 results surpassing expectations, prompting analyst target raises.

Company-level read

Ticker impact

$GKOSBullishHigh confidence
Context

Q2 2026 earnings beat estimates with $185.6M revenue and raised full-year outlook.

Expected impact

upward pressure on GKOS

Evidence & confidence

Revenue beat and upgraded targets suggest continued growth, supporting a bullish stance.

Market effects

Sector

Positive signal for medical technology sector, may lift peers.

Regional

U.S. biotech and medtech stocks could see modest gains.

Global

Limited to investors focused on U.S. healthcare equities.

Counterpoint

What could challenge this read

Valuation appears stretched; price targets may be overly optimistic.

Key entities

  • company
    Glaukos Corp

    Medical technology firm reporting strong Q2 earnings.

  • analyst
    H.C. Wainwright

    Raised price target to $195.

Read at source← All news

Related articles

AUG 20
$GKOSMed

GKOS Stock Surges 67% Year to Date: What's Driving the Rally?

Glaukos (GKOS) shares have risen 67.9% year-to-date, driven by strong revenue growth and product launches. Q2 revenue increased 49.5% to $185.6M, prompting raised 2026 guidance to $680-700M. Growth is attributed to iDose TR and Epioxa, with international expansion and a broad pipeline also contributing. Competitors include Alcon (ALC), Sight Sciences (SGHT), and AbbVie (ABBV). Risks include reimbursement and competition.

tradingview.com2 min
AUG 8
$GKOSMedAI 8/10

Glaukos (GKOS) Q2 2026 Earnings Call Transcript

Glaukos (NYSE: GKOS) reported Q2 2026 net sales of $185.6 million, up 50% year over year. U.S. glaucoma sales were $118.5 million, and iDose TR revenue was about $74 million. The company raised full-year 2026 net sales guidance to $680 million to $700 million and iDose TR revenue guidance to $275 million to $280 million.

aol.com7 min
JUL 30
$GKOSHighAI 9/10

Glaukos Q2 Earnings Beat Estimates on iDose TR Growth, Stock Up

Glaukos (GKOS) reported Q2 2026 adjusted loss of 14 cents per share, better than the Zacks Consensus loss of 28 cents. Revenue rose to $185.6 million, up 50% year over year, beating the consensus by 24.1%. Management raised 2026 net sales guidance to $680 million to $700 million. Shares rose 9.8% in after-hours.

tradingview.com6 min
JUL 30
$GKOSMed

Glaukos Q2 Earnings Call Highlights

Glaukos (NYSE:GKOS) reported Q2 updates on iDose TR, including acceleration across Medicare Administrative Contractor regions and no material demand pull-forward from proposed LCDs. International glaucoma revenue rose to $36.6M (+17%); corneal health revenue rose 48% to $30.4M with ~$11M Epioxa. Gross margin was ~85%. Full-year targets: gross margin 84% to 86%, corneal health growth ~20%.

finance.yahoo.com4 min
JUL 29
$GKOSMedAI 8/10

GLAUKOS Corp (GKOS): Results of Operations and Financial Condition

GLAUKOS Corp (GKOS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.2 3 gkos-ex99_2.htm EX-99.2 EX-99.2 Exhibit 99.2 JULY 29, 2026 GLAUKOS CORPORATION (NYSE: GKOS) SECOND QUARTER 2026 IN REVIEW Important Information This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designe

SEC EDGAR 8-K6 min